MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Depreciation & Amortization 2011-2026 | ANIX
Annual Depreciation & Amortization Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 38.3 K | 47.6 K | 18.4 K | 43.2 K | 33.3 K | 12.5 K | 314 K | - | 7.23 K | 7.98 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 314 K | 7.23 K | 58.1 K |
Quarterly Depreciation & Amortization Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15 K | 38.3 K | 29.4 K | - | 6.13 K | 33 K | 18.1 K | 126 K | 4.39 K | 12.4 K | 7.37 K | 81.3 K | 10.5 K | 32.1 K | 21.3 K | 81.3 K | 3.85 K | 24.9 K | 13.9 K | 81.3 K | 1.02 K | 244 K | 81.3 K | 81.3 K | 70.5 K | 233 K | 81.3 K | 81.4 K | 1.42 K | - | - | - | 2.08 K | - | - | - | 1.93 K | 5.99 K | 3.98 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 244 K | 1.02 K | 47.8 K |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
47 M | $ 8.93 | 0.68 % | $ 595 M |  USA |
 |
Castle Biosciences
CSTL
|
16 M | $ 25.81 | -0.08 % | $ 717 M | USA |
 |
Aspira Women's Health
AWH
|
264 K | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
252 M | $ 67.83 | 2.24 % | $ 26.5 B | USA |
 |
Guardant Health
GH
|
39.7 M | $ 88.44 | 1.45 % | $ 11.1 B | USA |
 |
Charles River Laboratories International
CRL
|
403 M | $ 153.93 | 1.29 % | $ 7.63 B | USA |
 |
CareDx, Inc
CDNA
|
15 M | $ 17.54 | 1.27 % | $ 935 M | USA |
 |
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
125 M | $ 103.98 | 0.12 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M |  China |
 |
IQVIA Holdings
IQV
|
1.14 B | $ 168.58 | 2.24 % | $ 29 B | USA |
 |
Fulgent Genetics
FLGT
|
24.9 M | $ 15.54 | 3.95 % | $ 470 M | USA |
|
Biodesix
BDSX
|
5.77 M | $ 16.96 | -1.91 % | $ 2.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
488 M | $ 99.21 | 1.63 % | $ 8.18 B |  Irlanda |
 |
Danaher Corporation
DHR
|
750 M | $ 195.14 | 1.96 % | $ 139 B | USA |
 |
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
13 M | $ 1.42 | 4.41 % | $ 426 M | USA |
 |
Illumina
ILMN
|
354 M | $ 122.1 | 2.36 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
570 M | $ 198.46 | -0.24 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
203 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
321 M | $ 113.8 | 1.76 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
14 M | $ 1.13 | 1.67 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
473 K | $ 9.04 | 7.36 % | $ 256 M |  Israel |
 |
NeoGenomics
NEO
|
36.1 M | $ 8.31 | 0.85 % | $ 1.06 B | USA |
 |
Neogen Corporation
NEOG
|
119 M | $ 9.22 | 1.21 % | $ 2 B | USA |
 |
Lantheus Holdings
LNTH
|
70.1 M | $ 80.11 | 2.05 % | $ 5.41 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
1.23 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
27.2 M | $ 457.31 | 0.81 % | $ 13.2 B | USA |
 |
Motus GI Holdings
MOTS
|
451 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 218.7 | 1.67 % | $ 25.1 B |  Schweiz |
 |
Celcuity
CELC
|
130 K | $ 115.13 | 0.2 % | $ 4.54 B | USA |
 |
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
7.62 M | $ 17.58 | 1.03 % | $ 393 M | USA |
 |
Invitae Corporation
NVTA
|
142 M | - | - | $ 21.2 M | USA |
 |
Twist Bioscience Corporation
TWST
|
24.9 M | $ 47.21 | 4.89 % | $ 2.82 B | USA |
 |
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
16.7 M | $ 199.94 | 1.14 % | $ 19.7 B | USA |